2 results
Approved WMOCompleted
Primary: The co-primary objectives of this study are* to compare independently adjudicated progression-free survival (PFS) following treatment with neratinib pluscapecitabine versus lapatinib plus capecitabine in patients with HER2-positive (HER2+)…
Approved WMOCompleted
The objective of this investigation is to describe visual outcomes and assess the safety at 12 months (330 - 420 days) post bilateral implantation of the AcrySof® IQ PanOptix* Presbyopia correcting IOL Model TFNT00.